ADVERUM BIOTECHNOLOGIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.19 USD | -2.13% |
|
-18.96% | +22.08% |
| 21/03 | Adverum Biotechnologies Files $200 Million Mixed Shelf | MT |
| 19/03 | RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk | MT |
Chart calendar Adverum Biotechnologies, Inc.
270f42841af75b119565.c2jwfbbNz0WH5ZPi5IoS0WH6fWeo_L2d8ppy32zSleo.AV_DP-K5qQz3gMSpu7pktgS3RDfwsuXbo-s0j1y456sJBMcIhZmHAc3Vwg~4d941ec930e035f23a40b659603fe716
Upcoming events on Adverum Biotechnologies, Inc.
Past events on Adverum Biotechnologies, Inc.
| 19/03/2024 01:35 am | Q4 2023 Earnings Release |
| 05/03/2024 07:40 pm | TD Cowen Health Care Conference |
| 13/02/2024 10:30 pm | Oppenheimer Healthcare Life Sciences Conference |
| 08/02/2024 09:26 pm | Macula Society Meeting |
| 08/02/2024 06:30 pm | Ixoberogene Soroparvovec LUNA Phase 2 Study Results Call |
| 30/11/2023 02:20 am | Evercore ISI HealthCONx Conference |
| 10/11/2023 02:35 am | Q3 2023 Earnings Release |
| 11/10/2023 | Cell & Gene Meeting on the Mesa Conference |
| 02/10/2023 10:30 pm | Chardan Genetic Medicines Conference |
| 28/09/2023 05:30 pm | Cantor Global Healthcare Conference |
| 13/09/2023 02:30 am | H.C. Wainwright Global Investment Conference |
| 16/08/2023 04:30 pm | H.C. Wainwright Ophthalmology Virtual Conference |
| 11/08/2023 01:35 am | Q2 2023 Earnings Release |
| 09/06/2023 08:30 pm | Annual General Meeting |
| 09/06/2023 07:30 pm | Jefferies Global Healthcare Conference |
| 20/05/2023 12:30 am | American Society of Gene Cell Therapy Meeting - Abstract Number : 1557 |
| 19/05/2023 02:30 am | American Society of Gene Cell Therapy Meeting - Abstract Number : 139 |
| 19/05/2023 12:30 am | American Society of Gene & Cell Therapy Meeting - Abstract Number : 976 |
| 18/05/2023 04:45 am | American Society of Gene Cell Therapy Meeting - Abstract Number : 76 |
| 18/05/2023 01:05 am | RBC Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,25 0,42 -40.48% | 0,00 0,07 - | 7,50 7,50 0% | 0,00 0,00 - | 3,60 3,67 -1.82% | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -67,0 -65,0 -3.03% | -114 -108 -5.24% | -141 -132 -7.18% | -151 -166 9.27% | -118 -132 10.34% | -111 |
|
EBIT Million USD | Released Forecast Spread | -68,5 -68,7 0.16% | -118 -112 -5.48% | -146 -146 -0.38% | -157 -158 0.49% | -124 -131 5% | -117 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -64,5 -65,0 0.73% | -116 -110 -5.94% | -146 -153 4.62% | -154 -154 -0.45% | -118 -126 6% | -112 |
|
Net income Million USD | Released Forecast Spread | -64,5 -65,0 0.73% | -118 -110 -6.96% | -146 -145 -0.33% | -155 -157 1.34% | -117 -126 7.08% | -111 |
|
EPS USD | Released Forecast Spread | -10,1 -10,1 0.33% | -13,8 -13,1 -5.26% | -14,8 -14,8 0% | -15,6 -15,9 2.01% | -11,6 -12,6 8.06% | -5,40 |
| Announcement Date | 12/03/20 | 01/03/21 | 29/03/22 | 30/03/23 | 18/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 3,60 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -33,1 -20,0 -65.49% | -36,7 -20,0 -83.54% | -42,4 -22,0 -92.83% | -39,2 -32,0 -22.65% | -32,2 -43,0 25.05% | -28,6 -34,0 15.74% | -31,5 -36,0 12.41% | -33,0 -35,0 5.66% | -25,1 -35,0 28.15% | -27,0 | -27,0 | -28,0 | -29,0 | -34,0 |
|
EBIT Million USD | Released Forecast Spread | -34,4 -34,1 -0.94% | -38,1 -29,3 -30% | -44,0 -37,3 -18.19% | -41,0 -31,7 -29.59% | -33,9 -35,3 3.76% | -30,2 -32,2 6.08% | -33,1 -34,3 3.6% | -34,5 -32,7 -5.63% | -26,2 -33,7 22.31% | -27,0 | -28,2 | -29,9 | -31,8 | -33,9 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -34,4 -41,5 17.02% | -37,9 -33,8 -12.1% | -43,7 -37,1 -18.06% | -40,1 -31,3 -28.33% | -32,7 -32,0 -2.11% | -29,0 -30,7 5.49% | -31,5 -31,9 1.37% | -32,9 -31,0 -5.86% | -24,8 -32,4 23.28% | -25,8 | -26,8 | -28,8 | -30,8 | -31,5 |
|
Net income Million USD | Released Forecast Spread | -34,4 -34,0 -1.27% | -37,9 -29,2 -29.82% | -43,8 -32,0 -36.61% | -40,1 -31,5 -27.35% | -32,7 -34,8 5.89% | -29,1 -31,5 7.9% | -31,5 -33,0 4.37% | -32,9 -31,8 -3.27% | -23,7 -32,7 27.51% | -25,8 | -26,8 | -28,5 | -30,0 | -32,6 |
|
EPS USD | Released Forecast Spread | -3,50 -3,43 -1.94% | -3,80 -3,10 -22.58% | -4,40 -3,23 -36.08% | -4,00 -3,45 -15.94% | -3,30 -3,62 8.84% | -2,90 -3,13 7.2% | -3,10 -3,25 4.62% | -3,30 -3,15 -4.76% | -2,30 -3,37 31.68% | -1,42 | -1,32 | -1,33 | -1,37 | -1,55 |
| Announcement Date | 29/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 30/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 18/03/24 | - | - | - | - | - |
More events
Past sector events for Adverum Biotechnologies, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ADVM Stock
- Calendar Adverum Biotechnologies, Inc.
